Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer
| Autor: | Pia-Allison E Roa, Rima Bazzi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Anti-HIV Agents Pyridones medicine.medical_treatment Human immunodeficiency virus (HIV) HIV Infections Dermatology Emtricitabine medicine.disease_cause Tenofovir alafenamide Piperazines Pancreatic cancer Internal medicine Percutaneous endoscopic gastrostomy Oxazines Medicine Humans Pharmacology (medical) Tenofovir Aged Alanine Bictegravir business.industry Adenine Public Health Environmental and Occupational Health HIV medicine.disease Dysphagia Antiretroviral therapy Amides Pancreatic Neoplasms Infectious Diseases Treatment Outcome medicine.symptom business Heterocyclic Compounds 3-Ring medicine.drug |
| Zdroj: | International journal of STDAIDS. 33(1) |
| ISSN: | 1758-1052 |
| Popis: | We present the case of a 78-year-old African American man with a history of human immunodeficiency virus diagnosed in 2007 who was newly diagnosed with pancreatic cancer. A percutaneous endoscopic gastrostomy tube was placed during the initial inpatient visit of pancreatic cancer diagnosis due to persistent dysphagia. Due to PEG placement and the patient’s wish to continue his previous antiretroviral therapy, the patient crushed his fixed-dose bictegravir/emtricitabine/tenofovir alafenamide under the direction of a physician and has maintained virologic suppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|